ArticleCell host & microbe2014
HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria.
Open access · bronzeAbstract read
In one paragraph
Article in Cell host & microbe, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.
0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed
6.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 118 citations in OpenAlex.
- Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection.The Journal of clinical investigation · 2022Trial
- Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination.PloS one · 2019Trial
- Understanding indeterminate HIV serology through antigen-band pattern analysis of INNO-LIA and recomLine HIV confirmatory assays.Scientific reports · 2026Article
- Cell-free RNA reveals host and microbial correlates of broadly neutralizing antibody development against HIV.PLoS pathogens · 2026Article
- Article
- Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity.Journal of virology · 2025Article
- The State of the Science on Chronic Comorbidities and Aging in Children and Adolescents with perinatally-acquired HIV.Current HIV/AIDS reports · 2025Review
- Antibiotic-induced gut microbiome perturbation alters the immune responses to the rabies vaccine.Cell host & microbe · 2025Article
- Activation of CXCR3Journal of virology · 2025Article
- On the carrying capacity of the bone marrow survival niche in mice.Frontiers in immunology · 2025Article
- Gastrointestinal germinal center B cell depletion and reduction in IgAScience immunology · 2024Article
- Review
- Oral tolerance to systemic vaccination remains intact without RORγt expression in regulatory T cells.iScience · 2023Article
- HIV-1 treatment timing shapes the human intestinal memory B-cell repertoire to commensal bacteria.Nature communications · 2023Article
- Defining and Studying B Cell Receptor and TCR Interactions.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Mixed Origins: HIV gp120-Specific Memory Develops from Pre-Existing Memory and Naive B Cells Following Vaccination in Humans.AIDS research and human retroviruses · 2023Article
- Unexpectedly higher levels of anti-orthopoxvirus neutralizing antibodies are observed among gay men than general adult population.BMC medicine · 2023Article
- Probiotic Therapy During Vaccination Alters Antibody Response to Simian-Human Immunodeficiency Virus Infection But Not to Commensals.AIDS research and human retroviruses · 2023Article
- Neonatal SHIV infection in rhesus macaques elicited heterologous HIV-1-neutralizing antibodies.Cell reports · 2023Article
- The Role of Immunity in the Pathogenesis of SARS-CoV-2 Infection and in the Protection Generated by COVID-19 Vaccines in Different Age Groups.Pathogens (Basel, Switzerland) · 2023Review
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 4 institutions in 1 country.
Ashley M TramaDuke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Immunology, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA. Electronic address: ashley.trama@dm.duke.edu.
M Anthony MoodyDuke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Pediatrics, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
S Munir AlamDuke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
Frederick H JaegerDuke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
Bradley LockwoodDuke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
Robert ParksDuke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
Krissey E LloydDuke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
Christina StolarchukDuke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
Richard ScearceDuke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
Andrew FoulgerDuke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
Dawn J MarshallDuke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
John F WhitesidesDuke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
Thomas L JeffriesDuke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
Kevin WieheDuke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
Lynn MorrisCentre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg 2131, South Africa.
Bronwen LambsonCentre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg 2131, South Africa.
Kelly SoderbergDuke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
Kwan-Ki HwangDuke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
Georgia D TomarasDuke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Surgery, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Molecular Genetics and Microbiology, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
Nathan VandergriftDuke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
Katherine J L JacksonDepartment of Pathology, Stanford University, Palo Alto, CA 94305, USA.
Krishna M RoskinDepartment of Pathology, Stanford University, Palo Alto, CA 94305, USA.
Scott D BoydDepartment of Pathology, Stanford University, Palo Alto, CA 94305, USA.
Thomas B KeplerDepartment of Microbiology, Boston University, Boston, MA 02215, USA.
Hua-Xin LiaoDuke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
Barton F HaynesDuke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Immunology, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA. Electronic address: barton.haynes@dm.duke.edu.
Duke University · USPalo Alto University · USNational Institute for Communicable DiseasesBoston University · US
Funding
Viral Sequencing CoreU19AI067854 · NIAID · DUKE UNIVERSITY · PI CRUMP, JOHN ANDREW · 2006 to 2011
$290.5MVirus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MCMICHAEL, ANDREW JAMES · 2012 to 2018
$204.7MViral Oncology Training GrantT32CA009111 · NCI · DUKE UNIVERSITY · PI LUFTIG, MICAH A. · 1985 to 2023
$8.9MNCI NIH HHS T32 CA009111NCI NIH HHS T32-CA009111NIAID NIH HHS U19 AI067854NIAID NIH HHS U19-AI067854NIAID NIH HHS UM1 AI100645NIAID NIH HHS UM1-AI100645-01
Abstract
Monoclonal antibodies derived from blood plasma cells of acute HIV-1-infected individuals are predominantly targeted to the HIV Env gp41 and cross-reactive with commensal bacteria. To understand this phenomenon, we examined anti-HIV responses in ileum B cells using recombinant antibody technology and probed their relationship to commensal bacteria. The dominant ileum B cell response was to Env gp41. Remarkably, a majority (82%) of the ileum anti-gp41 antibodies cross-reacted with commensal bacteria, and of those, 43% showed non-HIV-1 antigen polyreactivity. Pyrosequencing revealed shared HIV-1 antibody clonal lineages between ileum and blood. Mutated immunoglobulin G antibodies cross-reactive with both Env gp41 and microbiota could also be isolated from the ileum of HIV-1 uninfected individuals. Thus, the gp41 commensal bacterial antigen cross-reactive antibodies originate in the intestine, and the gp41 Env response in HIV-1 infection can be derived from a preinfection memory B cell pool triggered by commensal bacteria that cross-react with Env.
Indexed as
Antibody SpecificityAntigens, BacterialCross ReactionsHIV-1HIV AntibodiesHIV Envelope Protein gp41HIV InfectionsHumansIleumMicrobiotaMolecular Sequence DataPlasma CellsProtein BindingAntigens, Bacterialgp41 protein, Human immunodeficiency virus 1HIV AntibodiesHIV Envelope Protein gp41
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.